Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -11.11%45 EV-to-OCF is 7.00 as of Sep. 16, 2026, which is 230% above its 10-year median of 2.12. GuruFocus rates PBSV with a GF Score™ of 45/100 and a GF Value™ of $0.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 685 Healthcare Providers & Services companies, Pharma-Bio Serv ranks better than 69.2% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Pharma-Bio Serv's Enterprise Value is $-1.67 Mil.
Pharma-Bio Serv's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.24 Mil. Therefore, Pharma-Bio Serv's EV-to-OCF for today is 7.00.
The historical rank and industry rank for Pharma-Bio Serv's EV-to-OCF or its related term are showing as below:
PBSV'
s EV-to-OCF Range Over the Past 10 Years
Min: -61.55 Med: 2.12 Max: 63.79
Current: 4.01
During the past 13 years, the highest EV-to-OCF of Pharma-Bio Serv was 63.79. The lowest was -61.55. And the median was 2.12.
PBSV's EV-to-OCF is ranked better than 69.2% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 8.65
vs PBSV: 4.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharma-Bio Serv's PE Ratio (TTM) for today is calculated as:
Pharma-Bio Serv's share price for today is $0.40.
Pharma-Bio Serv's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharma-Bio Serv EV-to-OCF Related Terms
Pharma-Bio Serv EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pharma-Bio Serv's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's EV-to-OCF falls into.
Pharma-Bio Serv's current Enterprise Value is $-1.67 Mil.
Pharma-Bio Serv's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a EV-to-OCF of 7.00 as of Sep. 16, 2026. This is 230% above median its historical median of 2.12. According to the industry distribution chart, Pharma-Bio Serv ranks #211 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 30.8%.
Is Pharma-Bio Serv's EV-to-OCF too high?
Pharma-Bio Serv's current EV-to-OCF of 7.00 is 230% above median its 10-year median of 2.12. The Healthcare Providers & Services industry median EV-to-OCF is 8.65. Pharma-Bio Serv's value of 7.00 is 19.1% below this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #211 out of 685 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pharma-Bio Serv has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's EV-to-OCF compare to HCTI and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #211 out of 685 companies for EV-to-OCF. This puts Pharma-Bio Serv in the upper half of its industry. The industry median EV-to-OCF is 8.65. Pharma-Bio Serv's value of 7.00 is 19.1% below this benchmark. While the company's 10-year median is 2.12 vs. the industry median of 8.65, Pharma-Bio Serv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.65, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current EV-to-OCF of 7.00 is 19.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current EV-to-OCF is 7.00, which is 230% above median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Possible Value Trap. The stock's GF Value™ is $0.61, compared to a current price of $0.40 — trading 34.4% below its estimated fair value. The current EV-to-OCF is 7.00, which is 230% above median its 10-year median of 2.12 and 19.1% below the Healthcare Providers & Services industry median of 8.65. Pharma-Bio Serv's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current EV-to-OCF is 7.00 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.40 is trading 34.4% below its estimated GF Value™ of $0.61.
GuruFocus considers Pharma-Bio Serv to be Possible Value Trap.
Key valuation signals for PBSV:
EV-to-OCF: 7.00 (230% above median its 10-year median of 2.12)
GF Value™: $0.61 vs. price of $0.40 (34.4% below fair value)
Industry Position: 19.1% below the Healthcare Providers & Services median (#211 of 685)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
45GF Score
Get the complete analysis for PBSV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
